Generated static export from Obsidian-friendly vault markdown
ClinPharm Vault

Remibrutinib

Overview

  • Priority class: BTK
  • Mechanistic bucket: Bruton's tyrosine kinase pathway program
  • Sponsor: Novartis Pharmaceuticals
  • Alias(es): LOU064
  • Development shape in the current raw-source layer: foundational phase 2b CSU dose-finding, pivotal REMIX phase 3 CSU program, extension/lifecycle studies, late-stage CIndU expansion, comparator studies, and real-world follow-up.

Strategy readout

  • Headline: Broad BTK franchise strategy: establish CSU depth first, then layer on lifecycle, comparator, pediatric, CIndU, and real-world expansion.
  • Current strategic read: The current local source layer suggests Novartis is treating remibrutinib as a platform urticaria program rather than a single pivotal asset. CSU is the deepest evidence base, but the surrounding studies show deliberate expansion into lifecycle management, differentiation versus standards, CIndU growth, and post-approval evidence generation.
  • Highest visible phase in current registry: Phase 3
  • Strategy confidence in current local layer: High

Why this looks like the strategy

  • The CSU package is unusually dense: phase 2b core and extension, paired REMIX phase 3 studies, long-term follow-up, regional expansion, and dedicated safety work.
  • Comparator, adolescent, and mixed-CU studies suggest the sponsor is broadening both label reach and positioning, not only finishing the core adult CSU story.
  • The CIndU basket study and later real-world studies indicate the program is being extended beyond classic pivotal CSU into franchise-level expansion.

What to watch next

  • How strongly the CIndU branch matures relative to the already dense CSU package.
  • Whether comparator studies become mainly differentiation tools or major label-shaping assets.

Operational study design view

Trial Arms in registry Active dose regimens Total enrollment Per-arm sample size summary
NCT03926611 7 6 311 ClinicalTrials.gov results-section denominators support randomized group sizes of 44 (Arm 1), 44 (Arm 2), 47 (Arm 3), 44 (Arm 4), 44 (Arm 5), 45 (Arm 6), and 43 (placebo), totaling 311 participants.
NCT04109313 1 1 229 All participants n=229
NCT05030311 2 1 470 313 remibrutinib, 157 placebo.
NCT05032157 2 1 455 300 remibrutinib, 155 placebo.
NCT05048342 1 1 71 LOU064 25 mg b.i.d. n=71
NCT05170724 NR NR None The current CT.gov export does not provide a structured arm table or enrollment target for this managed-access record.
NCT05513001 3 1 696 696 total with a 1:1 allocation schema across 3 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT05677451 2 1 100 100 total with a 2:1 allocation schema across 2 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT05795153 1 1 144 LOU064 (remibrutinib) n=144
NCT05976243 6 1 362 362 total across 6 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT06042478 4 2 470 470 total across 4 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT06865651 4 2 44 Novartis trial-page text plus CT.gov support approximately 44 total participants across 4 listed arms and notes the study will attempt to enroll approximately 4 to 5 participants for each included chronic urticaria subtype; exact arm-specific counts are not explicitly stated in the current saved source text.
NCT06868212 2 2 400 400 total with a 1:1 allocation schema across 2 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT07358364 3 NR 3280 3280 total across 3 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT07358780 3 NR 505 505 total across 3 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT07408219 2 NR 350 350 total across 2 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.

Program map

Early CSU efficacy foundation

  • NCT03926611 - Phase 2; COMPLETED; Chronic Spontaneous Urticaria
  • Phase 2b dose-finding core study that established rapid CSU activity reduction across multiple oral remibrutinib dose regimens.
  • NCT04109313 - Phase 2; COMPLETED; Chronic Spontaneous Urticaria
  • Open-label extension for participants rolling over from the phase 2b core study.

Pivotal CSU program and lifecycle extension

  • NCT05030311 - Phase 3; COMPLETED; Chronic Spontaneous Urticaria
  • One of the two identical REMIX pivotal Phase 3 placebo-controlled CSU studies.
  • NCT05032157 - Phase 3; COMPLETED; Chronic Spontaneous Urticaria
  • Second identical REMIX pivotal Phase 3 placebo-controlled CSU study.
  • NCT05513001 - Phase 3; ACTIVE_NOT_RECRUITING; Chronic Spontaneous Urticaria
  • Phase 3 extension that includes randomized withdrawal plus long-term open-label cycles after the core pivotal studies.
  • NCT05048342 - Phase 3; COMPLETED; Chronic Spontaneous Urticaria
  • Open-label Japanese Phase 3 safety, tolerability, and efficacy study.
  • NCT05795153 - Phase 3; COMPLETED; Chronic Spontaneous Urticaria
  • Dedicated open-label ABPM study in adult CSU participants treated with remibrutinib.

Comparator, adolescent, and exploratory expansion studies

  • NCT05677451 - Phase 3; RECRUITING; Chronic Spontaneous Urticaria
  • Adolescent placebo-controlled Phase 3 study with PK and long-term extension components.
  • NCT06042478 - Phase 3; ACTIVE_NOT_RECRUITING; Chronic Spontaneous Urticaria
  • Phase 3b active-control study versus omalizumab with placebo and switch arms.
  • NCT06865651 - Phase 2; RECRUITING; Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
  • Exploratory mixed-CU study spanning CSU and multiple CIndU phenotypes with an explicit mechanism-of-action objective.
  • NCT06868212 - Phase 3; RECRUITING; Chronic Spontaneous Urticaria (CSU)
  • US Phase 3b head-to-head early-timepoint comparison against dupilumab.

CIndU and broader urticaria expansion

  • NCT05976243 - Phase 3; ACTIVE_NOT_RECRUITING; Chronic Inducible Urticaria
  • Basket study spanning symptomatic dermographism, cold urticaria, and cholinergic urticaria.

Access and real-world evidence layer

  • NCT05170724 - NR; AVAILABLE; Chronic Spontaneous Urticaria
  • Managed access cohort rather than a conventional randomized efficacy study.
  • NCT07358364 - NR; RECRUITING; Chronic Spontaneous Urticaria
  • Prospective non-interventional post-approval effectiveness and safety study.
  • NCT07358780 - NR; RECRUITING; Chronic Spontaneous Urticaria
  • US sub-study of the broader prospective real-world remibrutinib effectiveness program.
  • NCT07408219 - NR; RECRUITING; Chronic Spontaneous Urticaria
  • Early real-world comparative satisfaction/effectiveness survey against dupilumab.

Program Results Summary

Trials with source-backed results in the current local layer: 5 of 16

NCT03926611 (Published) - Primary endpoint (UAS7 change from baseline at week 4): LS mean ranged from -14.7 to -20.0 across 6 active dose regimens versus -5.4 for placebo; nominal P < 0.0001 for all doses versus placebo. - Most adverse events were mild or moderate with no dose-dependent pattern. - Sources: PMID 36096203

NCT04109313 (Published) - 194 of 230 (84.3%) patients from the core study entered the open-label treatment period (remibrutinib 100 mg BID). - Safety comparable to core study; most TEAEs mild-to-moderate. - Sources: PMID 37866460

NCT05030311 (Published) - Primary endpoint met: week-12 UAS7 LS mean change -20.0 (remibrutinib) versus -13.8 (placebo), P < 0.001. - AE and SAE rates similar between remibrutinib and placebo through week 24. - Sources: PMID 40043237; PMID 41115533

NCT05032157 (Published) - Primary endpoint met: week-12 UAS7 LS mean change -19.4 (remibrutinib) versus -11.7 (placebo), P < 0.001. - Safety profile consistent with REMIX-1; no new signals at 52 weeks. - Sources: PMID 40043237; PMID 41115533

NCT05976243 (Topline) - Primary endpoint met for all three CIndU subtypes: significantly higher complete response rates versus placebo at week 12 for symptomatic dermographism, cold urticaria, and cholinergic urticaria. - Well-tolerated; favorable safety profile; no liver safety concerns reported in topline release. - Sources: Novartis press release, 2026-02-18 (raw/sponsors/btk/remibrutinib/2026-cindu-phase-iii-remind-press-release.md)

Sponsor-sourced result evidence

Sponsor press releases complement the manuscript-backed REMIX results with topline framing of rapid onset, phase progression, durability, and CIndU expansion.

Novartis Phase III topline press release (August 2023) (Sponsor press release) - REMIX-1 and REMIX-2 both met all primary and secondary endpoints, showing clinically meaningful and statistically significant improvements in UAS7 at week 12 (sponsor press release; exact effect sizes reported in PMID 40043237). - Rapid onset of action illustrated by UAS7 improvement at week 2 in both REMIX studies. - Sponsor framing positions remibrutinib as the potential first-in-class oral BTK treatment for CSU in a decade. - Safety: Well-tolerated with a favorable safety profile; liver function tests balanced between active and placebo arms across both studies (sponsor press release). - Source(s): raw/sponsors/btk/remibrutinib/2023-phase-iii-primary-endpoints-press-release.md

Novartis 52-week sustained efficacy and safety press release (May 2024) (Sponsor press release) - UAS7 improvements observed as early as week 1 and sustained to week 52 in both REMIX-1 and REMIX-2. - At week 24, placebo-to-remibrutinib crossover patients showed response as early as 1 week after switching, sustained to end of study. - Almost half of patients were completely free of itch and hives (UAS7 = 0) at week 52 (sponsor press release; manuscript-level detail in PMID 41115533). - Safety: Favorable and consistent safety profile up to 52 weeks; liver transaminase elevations balanced across arms, all asymptomatic, transient, and reversible. - Safety: AEs, SAEs, and treatment discontinuations due to AEs comparable between remibrutinib and placebo during the 24-week placebo-controlled period; exposure-adjusted rates did not increase with long-term treatment. - Source(s): raw/sponsors/btk/remibrutinib/2024-sustained-efficacy-and-safety-press-release.md

Novartis RemIND CIndU Phase III press release (February 2026) (Sponsor press release) - Remibrutinib described as the first therapy to achieve a Phase III primary endpoint in CIndU. - Statistically significant and clinically meaningful complete response rates versus placebo at week 12 in all three CIndU subtypes: symptomatic dermographism, cold urticaria, and cholinergic urticaria. - sNDA submitted to FDA for symptomatic dermographism based on RemIND results. - Safety: Well-tolerated with no liver safety concerns reported in topline release. - Source(s): raw/sponsors/btk/remibrutinib/2026-cindu-phase-iii-remind-press-release.md

Longitudinal efficacy view

  • Plotted page: Remibrutinib longitudinal UAS7
  • Shared comparison page: Cross-program longitudinal UAS7 comparison
  • Current explicit numeric plotting coverage: derived mean UAS7 through weeks 0, 1, 2, 4, 12, and 24 for REMIX-1 and REMIX-2 separately.
  • Current responder plotting coverage: per-trial UAS7 <= 6 through weeks 1, 2, 12, and 24, plus pooled week 52 landmarks where explicit values were available.
  • Current main gap: exact week 52 mean UAS7 and per-trial week 52 UAS7 <= 6 values are still graph-only in the current local extraction and remain intentionally unplotted.
  • Local data backbone: data/remibrutinib_longitudinal_uas7.json and data/remibrutinib_longitudinal_uas7_notes.md.

Evidence summary

  • Primary manuscript layer is strongest for the CSU efficacy chain: phase 2b core (PMID 36096203), phase 2b extension follow-up (PMID 37866460), REMIX phase 3 core results (PMID 40043237), and 52-week REMIX follow-up (PMID 41115533).
  • The REMIX papers directly support the pivotal phase 3 pair NCT05030311 and NCT05032157, including trial names REMIX-1 and REMIX-2, randomized sample sizes, and week-12 plus week-52 efficacy framing.
  • The raw-source layer also shows remibrutinib extending beyond classical adult CSU registrational studies into adolescent, CIndU, active-comparator, managed-access, and real-world evidence records.

Inventory counts

  • CT.gov trials in registry: 16
  • Sponsor artifacts in registry: 4
  • Primary publications in registry: 4
  • Supporting publications in registry: 2

Primary publications

  • PMID 36096203 (2022, The Journal of allergy and clinical immunology): Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
  • Role: phase_2b_core
  • Linked trial IDs: NCT03926611
  • Local cache: raw/publications/pubmed/markdown/PMID36096203.md
  • PMID 37866460 (2024, The Journal of allergy and clinical immunology): Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
  • Role: phase_2b_extension
  • Linked trial IDs: NCT03926611
  • Local cache: raw/publications/pubmed/markdown/PMID37866460.md
  • PMID 40043237 (2025, The New England journal of medicine): Remibrutinib in Chronic Spontaneous Urticaria.
  • Role: phase_3_core
  • Linked trial IDs: NCT05030311, NCT05032157
  • Local cache: raw/publications/pubmed/markdown/PMID40043237.md
  • PMID 41115533 (2026, The Journal of allergy and clinical immunology): Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
  • Role: phase_3_long_term
  • Linked trial IDs: NCT05030311, NCT05032157
  • Local cache: raw/publications/pubmed/markdown/PMID41115533.md

Sponsor-source layer

  • 2023 Phase III primary endpoints press release (Novartis)
  • raw/sponsors/btk/remibrutinib/2023-phase-iii-primary-endpoints-press-release.html
  • raw/sponsors/btk/remibrutinib/2023-phase-iii-primary-endpoints-press-release.md
  • 2024 sustained efficacy and safety press release (Novartis)
  • raw/sponsors/btk/remibrutinib/2024-sustained-efficacy-and-safety-press-release.html
  • raw/sponsors/btk/remibrutinib/2024-sustained-efficacy-and-safety-press-release.md
  • 2026 CIndU Phase III RemIND press release (Novartis)
  • raw/sponsors/btk/remibrutinib/2026-cindu-phase-iii-remind-press-release.html
  • raw/sponsors/btk/remibrutinib/2026-cindu-phase-iii-remind-press-release.md
  • Novartis trial page NCT06865651 (Novartis)
  • raw/sponsors/btk/remibrutinib/novartis-trial-page-nct06865651.html
  • raw/sponsors/btk/remibrutinib/novartis-trial-page-nct06865651.md

Interpretation

  • Verified facts: remibrutinib is no longer represented here as a single flagship page. The current derived layer now exposes the broader study stack spanning early CSU, pivotal CSU, CIndU, comparator, and real-world records.
  • Interpretation: remibrutinib is currently the deepest BTK urticaria program in the local evidence stack because it combines dense CT.gov coverage with explicit manuscript linkage for the core CSU efficacy package.
  • Open questions:
  • Some remibrutinib records are lifecycle, managed-access, or real-world studies rather than classic interventional efficacy trials, so program-level summaries should keep those categories separate.
  • Several sponsor press releases remain program-level artifacts because the cached metadata did not capture explicit trial IDs, even when the topic clearly belongs to the remibrutinib program.
  • Additional manual enrichment is still needed if we want every remibrutinib study page to carry outcome-level or arm-level detail beyond the conservative CT.gov/manuscript layer.

Provenance

  • Primary source(s):
  • ../inventories/source_registry.json
  • ../inventories/source_registry.md
  • Supporting source(s):
  • ../inventories/ctgov_priority_trials.json
  • ../inventories/publication_priority_curation.json
  • ../inventories/sponsor_priority_sources.json
  • Last verified: 2026-04-08
  • Verification status: Partial

Change Log

  • 2026-04-08: Rebuilt the remibrutinib program page with study-family grouping and explicit linkage across the broader remibrutinib trial stack.